Pharmacogenomics and targeted therapy of cancer: Focusing on non-small cell lung cancer

摘要: Recent studies have been established high degree of genetic diversity in solid organ tumors among individuals and even between individual tumor cells. This intratumor intertumor results a heterogeneous with unique characteristics which potentially allows effective drug therapy. The goal pharmacogenomics is to elucidate the network(s) that underlie efficacy resistance. Advances targeted personalized therapy play an increasingly important role many common cancers, notably lung cancer, due incidence, prevalence, mortality greater tendency towards resistance seen these patients. Non-small cell cancer (NSCLC) characterized by mutations epidermal growth factor receptor (EGFR) or downstream kinase pathways. has led development highly selective monoclonal antibodies EGFR tyrosine inhibitors (EGFR-TKIs) prevent initiation, proliferation, differentiation, angiogenesis, survival, invasion. However, new treatments induced further pharmacogenomic analysis revealed associated increased reduced efficacy. Combinations targeting stem cells may increase success treating patients cancer.